Compare CBAN & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBAN | SPRY |
|---|---|---|
| Founded | 1975 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.6M | 473.4M |
| IPO Year | 1995 | 2020 |
| Metric | CBAN | SPRY |
|---|---|---|
| Price | $21.39 | $4.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 101.5K | ★ 1.4M |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 16.91 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $35.41 | $87.40 |
| Revenue Next Year | $4.84 | $81.64 |
| P/E Ratio | $23.84 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.80 | $4.73 |
| 52 Week High | $22.46 | $13.15 |
| Indicator | CBAN | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 28.41 |
| Support Level | $19.20 | N/A |
| Resistance Level | $21.78 | $8.61 |
| Average True Range (ATR) | 0.38 | 0.30 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 60.82 | 2.70 |
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.